证券代码：300289 证券简称：利德曼 公告编号：2023-050 北京利德曼生化股份有限公司 关于举行2023年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特此公告。 北京利德曼生化股份有限公司 北京利德曼生化股份有限公司（以下简称"公司"）已于 2023 年 8 月 12 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2023 年半年度报告》及《2023 年半年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于 2023 年 8 月 18 日（星期五）下午 15:00 至 16:00 时举行 2023 年半年 度业绩说明会。本次半年度业绩说明会将采取网络远程方式举行，投 资者可通过以下方式参与本次互动交流： 参与方式一：在微信中搜索"利德曼投资者关系小程序"； 参与方式二：微信扫描以下二维码： 投资者依据提示，授权登入"利德曼投资者关系"小程序，即可 参与交流。 为提升交流效率和针对性，以及做好中小投资者保护工作，广泛 听取投资者的意见和建议，增进投资者对公司的了解和认同，提升 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥226,953,339.05, a decrease of 39.36% compared to ¥374,278,326.17 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥16,488,022.38, down 31.12% from ¥23,935,722.03 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥13,526,480.11, a decline of 35.82% compared to ¥21,074,994.36 in the same period last year[19]. - The basic earnings per share decreased to ¥0.0303, down 31.14% from ¥0.0440 in the same period last year[19]. - The company achieved operating revenue of 226.95 million yuan, a decrease of 39.36% year-on-year, and a net profit attributable to shareholders of 16.49 million yuan, down 31.12% year-on-year[39]. - The net profit for the first half of 2023 was CNY 19,482,806.84, a decrease of 45.9% compared to CNY 35,931,602.78 in the same period of 2022[199]. - The operating profit for the first half of 2023 was CNY 24,274,616.60, down 46.0% from CNY 44,957,089.56 in the previous year[199]. - The total comprehensive income for the first half of 2023 was CNY 19,482,806.84, a decrease of 45.9% from CNY 35,931,602.78 in the previous year[200]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,936,870,025.87, a decrease of 3.02% from ¥1,997,134,641.92 at the end of the previous year[19]. - The company's total assets as of June 30, 2023, amounted to CNY 2,104,671,954.30, slightly up from CNY 2,102,669,961.22 at the beginning of the year[197]. - The company's current assets totaled CNY 1,080,916,720.28, down from CNY 1,110,505,444.50 at the beginning of the year, reflecting a decrease of approximately 2.5%[191]. - The total liabilities decreased to CNY 107,311,546.01 from CNY 173,885,049.05, a decline of 38.2%[197]. - The company's equity attributable to shareholders increased to CNY 1,997,360,408.29 from CNY 1,928,784,912.17, reflecting a growth of 3.4%[197]. Research and Development - The total R&D investment for the company in the reporting period was ¥16.48 million, a decrease of 1.69% year-on-year, representing 7.26% of the operating revenue[55]. - The company has invested in the development of 43 immunodiagnostic reagent projects, with 5 new projects added during the reporting period[54]. - The company is actively expanding into molecular diagnostics and POCT, with 3 projects in different stages of development for molecular diagnostic reagents[55]. - The company has established a research and development team of 77 people, accounting for 14.81% of the total workforce, with 33 holding master's degrees or higher[63]. - The company has developed proprietary technologies that enhance the sensitivity and stability of diagnostic products compared to similar products in the market[63]. Market and Product Development - The company is focusing on self-research and collaborative development to enhance product competitiveness, establishing a cross-departmental project management model[37]. - The company is actively expanding its overseas market presence, leveraging the growing influence of domestic in vitro diagnostic manufacturers abroad[40]. - The company is enhancing its marketing capabilities and product offerings, including the introduction of specialized testing projects and upgrades to its chemiluminescence detection systems[40]. - The company is in the product development stage for multiple immunoassay kits, including prostate-specific antigen (PAP) and various tumor markers, aiming to enhance cancer detection packages[56]. - The company is working on a series of immunoassay kits for inflammation and hormone detection, which will diversify its testing categories[56]. Environmental Compliance - The company is classified as a key pollutant discharge unit, adhering to strict environmental standards for wastewater and emissions management[112]. - Beijing Lidman invested CNY 18.17 million in environmental protection measures during the reporting period, including CNY 10.70 million for wastewater treatment and CNY 4 million for air pollution control[119]. - The company achieved a total wastewater discharge of 0.27 tons and a total annual discharge of 4.26 tons, with all pollutant emissions within the regulatory limits[114]. - The company has implemented an online monitoring system for wastewater, which has been operational since 2021 and is connected to the Beijing Ecological Environment Bureau[115]. - The company has maintained all pollutant emissions below the limits set by its discharge permits during the reporting period[116]. Governance and Compliance - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance structure[125]. - The company has established a comprehensive governance structure to protect shareholder rights and ensure compliance with relevant laws[125]. - The company guarantees that all related transactions with the listed company will be fair and conducted according to normal commercial practices, ensuring compliance with relevant regulations[136]. - The company has committed to ensuring that all related transactions are disclosed in accordance with legal and regulatory requirements, maintaining transparency with shareholders[136]. - The company has not engaged in any related party transactions during the reporting period[164]. Future Outlook - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% driven by new product launches and market expansion[139]. - The company plans to enhance its online sales platform, aiming for a 30% increase in e-commerce revenue by the end of 2023[140]. - The company has allocated 200 million RMB for research and development in innovative technologies over the next year[139]. - The company aims to enhance operational efficiency, targeting a reduction in operational costs by 15% by the end of 2023[139]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[139].

2、报告期内，公司不存在为控股股东及其他关联方、其他法人 单位或个人提供担保的情形。公司也不存在以前年度发生并累积至 2023 年 6 月 30 日的对外担保情形。 二、关于 2023 年半年度募集资金存放与实际使用情况专项报告 的独立意见 经核查，我们认为：公司 2023 年上半年对募集资金的存放和使 用管理严格按照有关法律、行政法规、规范性文件及公司相关制度的 要求，不存在募集资金存放和使用违规及变相改变募集资金用途的情 形，也不存在损害公司股东特别是中小投资者利益的情况。公司编制 的《2023 年半年度募集资金存放与实际使用情况的专项报告》内容 真实、准确、完整、不存在虚假记载、误导性陈述和重大遗漏。 独立董事：王艳、张志谦、安娜 北京利德曼生化股份有限公司独立董事 关于第五届董事会第十二次会议相关事项的独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等相关法律法规及规范性文件以及《北京利德曼生化股份有限公 司独立董事制度》的有关规定，我们作为北京利德曼生化股份有限公 司（以下简称"公司"）的独立董事，本着对全体股 ...

2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：北京利德曼生化股份有限公司 单位：人民币元 | | | 占用方与上 | 上市公司核 | | 年半年度 2023 | 年半年 2023 | 2023 年半年度 | 2023 年半年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | 资金占用方名 | 市公司的关 | 算的会计科 | 年期初占 2023 | 占用累计发生 | 度占用资金 | 偿还累计发生 | 期末占用资金余 | 占用形成 | 占用性质 | | 用 | 称 | | | 用资金余额 | 金额（不含利 | 的利息（如 | | | 原因 | | | | | 联关系 | 目 | | | | 金额 | 额 | | | | | | | | | 息） | 有） | | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | ...

证券代码：300289 证券简称：利德曼 公告编号：2023-045 北京利德曼生化股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")第五届董事会第 十二次会议(以下简称"本次会议")于 2023 年 8 月 11 日在北京市北京 经济技术开发区兴海路 5 号公司二层会议室以通讯方式召开。本次会 议通知于 2023 年 8 月 1 日以电子邮件方式送达全体董事，与会的各 位董事已知悉与所审议事项相关的必要信息。本次会议由董事长王凯 翔先生主持，应出席本次会议的董事 7 名，亲自出席会议的董事 7 名。 公司监事和高级管理人员列席了本次会议。本次会议的召集和召开符 合《公司法》和《公司章程》的有关规定，会议所形成的有关决议合 法、有效。经全体董事认真审议，表决通过以下议案： 一、审议通过《关于 2023 年半年度报告全文及摘要的议案》 董事会认为公司已严格按照相关法律、法规及中国证监会和深圳 证券交易所的规定，编制公司《2023 年半年度报告》及《2023 年半 年度报告 ...

证券代码：300289 证券简称：利德曼 公告编号：2023-046 北京利德曼生化股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）第五届监事会 第十次会议（以下简称"本次会议"）通知于 2023 年 8 月 1 日以电子 邮件方式向全体监事发出，与会的各位监事已知悉与所审议事项相关 的必要信息。本次会议于 2023 年 8 月 11 日在北京市北京经济技术开 发区兴海路 5 号公司二层会议室以通讯方式召开。出席会议的监事应 到 3 名，亲自出席监事 3 名，本次会议由公司监事会主席林冠宇先生 主持。本次会议的召开符合《中华人民共和国公司法》及《公司章程》 等法律、法规和内部制度的规定。会议以投票表决方式审议通过以下 议案： 一、审议通过《关于 2023 年半年度报告全文及摘要的议案》 公司监事会对《2023 年半年度报告》及《2023 年半年度报告摘 要》进行了审核，提出如下审核意见： 1、公司董事会编制和审核公司 2023 年半年度报告的程序符合法 律、行政法规、中 ...

2023 年半年度募集资金存放与实际使用情况 证券代码：300289 证券简称：利德曼 公告编号：2023-049 北京利德曼生化股份有限公司 的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号—上市公 司募集资金管理和使用的监管要求》（证监会公告〔2022〕15 号）、《深 圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》（深证上〔2022〕14 号）及相关格式指引的规定，北京利德曼生化 股份有限公司（以下简称"公司"）现将 2023 年半年度募集资金存放与 实际使用情况报告如下： 一、募集资金基本情况 (一)实际募集资金金额、资金到账情况 经中国证券监督管理委员会《关于同意北京利德曼生化股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2021〕519 号）同意 注册，公司向特定对象发行 126,213,152 股人民币普通股股票，发行价 格为 4.41 元/股，募集资金总额为人民币 556,600,000.32 元，扣除各项 发行费用（不含增值税）5,768,77 ...

中信建投证券股份有限公司 关于北京利德曼生化股份有限公司 2023 年半年度跟踪报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：利德曼 | | --- | --- | | 保荐代表人姓名：吴嘉煦 | 联系电话：010-65608214 | | 保荐代表人姓名：蔡诗文 | 联系电话：010-85130823 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 防止关联方占用公司资源的制度、募集资金管理制度、 | 是 | | 内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 2 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导情况 | | | （1） ...

Financial Performance - Revenue for Q1 2023 was CNY 108,150,382.74, a decrease of 43.55% compared to CNY 191,578,138.79 in the same period last year[5] - Net profit attributable to shareholders was CNY 8,296,310.96, down 31.49% from CNY 12,109,083.40 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.0153, a decrease of 30.45% from CNY 0.022 in the same period last year[5] - The total comprehensive income for Q1 2023 was CNY 10,109,371.69, compared to CNY 18,442,533.26 in Q1 2022, reflecting a decrease of approximately 45.0%[28] - Net profit for Q1 2023 was CNY 10,109,371.69, a decline of 45.0% compared to CNY 18,442,533.26 in Q1 2022[27] Cash Flow - Net cash flow from operating activities increased by 535.02% to CNY 27,508,461.89, compared to CNY 4,331,880.00 in the previous year[5] - Cash inflows from operating activities totaled CNY 142,616,871.69, a decrease from CNY 248,793,538.36 in the previous year, reflecting a decline of about 42.6%[30] - Cash outflows from operating activities were CNY 115,108,409.80, down from CNY 244,461,658.36, resulting in a net cash flow from operating activities of CNY 27,508,461.89, compared to CNY 4,331,880.00 in the previous year[31] - The net cash flow from investing activities improved by 87.03%, amounting to CNY -41,878,200.00, compared to CNY -322,868,300.00 in the same period last year[14] - The net cash flow from financing activities was CNY -2,782,067.94, an improvement from CNY -4,452,419.68 in the previous year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,941,239,161.02, a decrease of 2.80% from CNY 1,997,134,641.92 at the end of the previous year[5] - Total liabilities decreased to CNY 150,662,386.21 in Q1 2023 from CNY 216,667,238.80 in the same period last year[25] - Cash and cash equivalents at the end of the reporting period were RMB 781.66 million, down from RMB 798.81 million at the beginning of the year[23] - The company reported a decrease in accounts receivable to CNY 165,515,052.40 from CNY 184,081,260.63 year-over-year, indicating improved collection efforts[25] Business Segments - The in vitro diagnostic reagent business generated RMB 89.06 million in revenue, a decline of 46.15%, accounting for 82.34% of total revenue[18] - The diagnostic instruments (including accessories and consumables) segment reported revenue of RMB 4.83 million, down 61.96%, representing 4.47% of total revenue[18] Research and Development - Research and development expenses for Q1 2023 amounted to CNY 8,464,282.68, a decrease of 7.3% from CNY 9,130,522.32 in Q1 2022[27] - The company has four new products under registration and one new biochemical diagnostic reagent product has obtained registration certification[18] - The company added one new utility model patent and one new invention patent application during the reporting period[19] Shareholder Activities - The company completed a share buyback plan, with Vice President Ding Yaoliang purchasing 1,140,000 shares for a total of RMB 6.99 million[20] - The company paid a total of RMB 39.35 million as the remaining transfer price for acquiring a 51% stake in Guotuo (Xiamen) Cold Chain Logistics Co., Ltd.[21] Other Information - The company reported a 100% decrease in accounts payable, dropping to CNY 0.00 from CNY 1,967,200.00 due to the payment of matured acceptance bills[10] - The company's weighted average return on equity decreased to 0.48% from 0.66% year-on-year[5] - The company's total equity attributable to shareholders increased by 0.48% to CNY 1,735,601,004.17 from CNY 1,727,304,693.21 at the end of the previous year[5] - The Q1 2023 report was not audited, indicating that the figures are preliminary and subject to change[32]